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Adherence to pharmacologic therapy is a major challenge for the rational use of 
medicines, particularly when it comes to antiretroviral drugs that require adherence 
to at least 95% of prescribed doses.1 Studies in this area are always important and 
contribute to medication adherence understanding, even though there is no reference 
test for measuring this. Recently, an article was published in this journal that proposes 
the determination of lamivudine plasma concentration to validate patient self-reported 
adherence to antiretroviral treatment.2 In that study, serum levels obtained after 3 hours 
of ingestion of the last dose of the drug were compared with patient reports that were 
classified into different levels of adherence, based on their recall of missed doses in 
the previous 7 days.
It was hypothesized by the authors that the use of a biological marker for drug 
adherence was extremely important, given the relevance of the topic. However, 
we would like to draw attention to some points that may determine the success of 
the use of similar methods for this purpose. The formation of groups with similar 
anthropometric characteristics is relevant since the dose of lamivudine may have 
to be changed, depending, for example, on sex, weight, and age.3 Even information 
considered important by the authors of that study was not provided. There is a need 
for greater clarity on the eligibility criteria, especially with regard to the clinical stage 
of the disease, CD4 counts and viral load, associated diseases, and comorbidity, as 
well as the evaluation of kidney function and other medications used that can affect 
lamivudine pharmacokinetics.3
We also point out that the dosage used must be taken into account, because 
differences in the bioavailability of the drug may occur if the product is being used in 
a single daily dose or every 12 hours, and be influenced by the amount of lamivudine 
that the patient is using.4 Unfortunately, this information was not provided by the 
authors.
Another point worth mentioning is the recall period used as reference. Depending on 
the nature of the study, it is currently preferred that a 24 or 48 hour period be used. With 
respect to this study, for instance, a 7-day period would incorporate a weekend. In Brazil, 
we have observed that patients on antiretroviral therapy have lower adherence to treatment 
on weekends. Their routine can be altered during weekends. For example, often they 
drink alcohol and fail to use their medication for fear of adverse drug interactions.5
Finally, the study by Minzi et al2 suggested a high agreement rate (more than 80%) 
between self-reported patient adherence and antiretroviral plasma levels. However, 
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further studies may be able to strengthen this hypothesis using 
a correlation analysis that adopts a more robust statistical 
method to assess medication adherence.
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Galato et alWe agree with some of the points raised by the reader in the 
letter. We also understand that the use of a drug like lami-
vudine, which has such a short half-life, could be mislead-
ing, especially if a patient missed a dose and then takes the 
medication the morning of the day blood samples are to be 
collected. The patient must be trusted to accurately report 
whether they have taken the dose at home, since there is no 
way to verify this.
We did not recruit the study patients but used patient 
data available at the clinics since we wanted to find out 
what happens in real life at clinics treating human immu-
nodeficiency virus (HIV) in Tanzania. It was expected that, 
under normal circumstances, parameters such as liver and 
kidney function tests as well as body weight would be in 
the patient records. We did not want the patients to modify 
their drug-taking habits, so used information recorded by 
clinicians and nurses in patient records. It will be impor-
tant in the future to launch a similar study under direct 
observation of the investigators because this would enable 
control over the study conditions and determine all the 
necessary parameters and laboratory tests. At the moment, 
lamivudine-based highly active antiretroviral therapy is 
administered 12-hourly at the HIV clinics, and the study 
was based on adult patients.
Given that the objective of our study was not to relate 
a patient’s serum drug levels to their CD4 count or clini-
cal staging, we concentrated more on information about 
drug intake provided by patients to our research nurses and 
compared this with serum lamivudine concentrations. How-
ever, we agree that the use of a 7-day recall period concern-
ing missed doses could be unreliable. We would support the 
use of a period of 24–48 hours, as proposed by Galato.
Despite our encouraging findings, we are of the opinion 
that a similar study could be launched using a recall period 
of 24–48 hours and also a drug with a long half-life as a 
marker for adherence, as opposed to lamivudine which 
has a very short half-life and may not indicate a missed 
dose if a patient took the drug on the morning of the day 
the blood samples were to be collected. However, it is 
important to note that even drugs with a long half-life have 
some shortcomings when used for these types of studies. 
For instance, it may be difficult to identify a single missed 
dose during any given period after steady-state plasma 
levels are achieved. Further studies should be conducted 
to acquire data based on a 24–48 hour recall period using 
drugs with both long and short half-lives; of course, taking 
into consideration the renal and liver status of patients 
involved in such studies.
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